253 related articles for article (PubMed ID: 1336349)
1. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs.
Shen LL; Baranowski J; Fostel J; Montgomery DA; Lartey PA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2778-84. PubMed ID: 1336349
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase inhibitors as antifungal agents.
Shen LL; Fostel JM
Adv Pharmacol; 1994; 29B():227-44. PubMed ID: 8996610
[No Abstract] [Full Text] [Related]
3. Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery.
Fostel JM; Montgomery DA; Shen LL
Antimicrob Agents Chemother; 1992 Oct; 36(10):2131-8. PubMed ID: 1332588
[TBL] [Abstract][Full Text] [Related]
4. Identification of the aminocatechol A-3253 as an in vitro poison of DNA topoisomerase I from Candida albicans.
Fostel J; Montgomery D
Antimicrob Agents Chemother; 1995 Mar; 39(3):586-92. PubMed ID: 7793856
[TBL] [Abstract][Full Text] [Related]
5. Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking.
Fostel J; Montgomery D; Lartey P
FEMS Microbiol Lett; 1996 May; 138(2-3):105-11. PubMed ID: 9026436
[TBL] [Abstract][Full Text] [Related]
6. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of DNA topoisomerases I and II applied to Candida dubliniensis reduce growth, viability, the generation of petite mutants and toxicity, while acting synergistically with fluconazole.
Tagle-Olmedo T; Andrade-Pavón D; Martínez-Gamboa A; Gómez-García O; García-Sierra F; Hernández-Rodríguez C; Villa-Tanaca L
FEMS Yeast Res; 2021 Apr; 21(3):. PubMed ID: 33837766
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
Keller BA; Patel S; Fisher LM
Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):329-39. PubMed ID: 9164874
[TBL] [Abstract][Full Text] [Related]
9. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus.
Yamashita Y; Kawada S; Fujii N; Nakano H
Biochemistry; 1991 Jun; 30(24):5838-45. PubMed ID: 1646001
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity of eupolauridine and its action on DNA topoisomerases.
Khan SI; Nimrod AC; Mehrpooya M; Nitiss JL; Walker LA; Clark AM
Antimicrob Agents Chemother; 2002 Jun; 46(6):1785-92. PubMed ID: 12019091
[TBL] [Abstract][Full Text] [Related]
11. Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282.
Kohlbrenner WE; Wideburg N; Weigl D; Saldivar A; Chu DT
Antimicrob Agents Chemother; 1992 Jan; 36(1):81-6. PubMed ID: 1317151
[TBL] [Abstract][Full Text] [Related]
12. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.
Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A
Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerases from Streptomyces noursei: influence of coumarins and quinolones on the enzymic activity.
Störl K; Störl J; Roth M; Zimmer C
Biochim Biophys Acta; 1994 Mar; 1199(2):143-8. PubMed ID: 8123663
[TBL] [Abstract][Full Text] [Related]
15. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
Tewey KM; Chen GL; Nelson EM; Liu LF
J Biol Chem; 1984 Jul; 259(14):9182-7. PubMed ID: 6086625
[TBL] [Abstract][Full Text] [Related]
16. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
17. A new 1-nitro-9-aminoacridine derivative targeting yeast topoisomerase II able to overcome fluconazole-resistance.
Rząd K; Paluszkiewicz E; Gabriel I
Bioorg Med Chem Lett; 2021 Mar; 35():127815. PubMed ID: 33486051
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells.
Dykstra CC; McClernon DR; Elwell LP; Tidwell RR
Antimicrob Agents Chemother; 1994 Sep; 38(9):1890-8. PubMed ID: 7810995
[TBL] [Abstract][Full Text] [Related]
19. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
